Publication | Closed Access

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

UrologyPd-l1 InhibitorsGenitourinary CancerMedicineEnfortumab VedotinImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyCisplatin-ineligible PatientsMolecular Oncology